An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

Phase 2 Terminated 16 enrolled Bristol-Myers Squibb

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of BMS-986165 compared with placebo with regard to measures of kidney function in participants with lupus nephritis (LN).

Timeline

Start: 2019-07-15
Primary completion: 2020-10-29
Completion: 2021-09-17

Outcome

Outcome not reported

Stopped (Enrollment): “Insufficient enrollment”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CRAVACITINIB	Small molecule	—	—
Background	Mycophenolate Mofetil	Small molecule	—	—

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

Summary

Timeline

Outcome

Drugs

Indications